Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group-Reference-Cited by-同舟云学术

Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: A retrospective analysis of the ALL-REZ BFM Study Group

Published:2011-01 Issue:1 Volume:47 Page:90-97
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

von Stackelberg Arend,Völzke Enrico,Kühl Jörn-Sven,Seeger Karl,Schrauder André,Escherich Gabriele,Henze Günter,Tallen Gesche

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Treatment of childhood acute lymphoblastic leukemia;Stanulla;Semin Hematol,2009

2. Treatment of relapsed acute lymphoblastic leukemia;Henze,2002

3. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St. Jude Children’s Research Hospital;Pui;Blood,2004

4. Initial results of a study of the treatment of children with ALL recurrences;Henze;Onkologie,1986

5. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM Group;Henze;Blood,1991

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Models, Same Results: Considerations When Choosing Between Approaches to Model Cost Effectiveness of Chimeric-Antigen Receptor T-Cell Therapy Versus Standard of Care;PharmacoEconomics;2024-09-07

2. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy;Value in Health;2024-04

3. Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study;Blood Advances;2024-01-12

4. A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults;Cytotherapy;2023-09

5. Allo or auto CAR-T cells for refractory BCP-ALL?;Blood;2023-07-13